Nektar Therapeutics (NKTR) Shares are Down -2.39%

Nektar Therapeutics (NKTR) has risen sharply, recording gains of 11.07% in the past 4 weeks. However, the stock has corrected -2.39% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 9.93% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 4.92% and the 50-Day Moving Average is 10.17%. Nektar Therapeutics (NASDAQ:NKTR): On Fridays trading session , Opening price of the stock was $17.21 with an intraday high of $17.225. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $16.89. However, the stock managed to close at $17.16, a loss of 0.29% for the day. On the previous day, the stock had closed at $17.21. The total traded volume of the day was 501,756 shares.


The company Insiders own 6.76% of Nektar Therapeutics shares according to the proxy statements.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.